These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6939914)

  • 1. Factors influencing the binding of N-2-fluorenylacetamide to specific regions of the hepatic genome in vivo in rats.
    Schwartz EL; Braselton WE; Goodman JI
    J Natl Cancer Inst; 1981 Apr; 66(4):667-72. PubMed ID: 6939914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent binding of 2-acetylaminofluorene, 2-aminofluorene, and N-hydroxy-2-acetylaminofluorene to rat liver nuclear DNA and protein in vivo and in vitro.
    Stout DL; Hemminki K; Becker FF
    Cancer Res; 1980 Oct; 40(10):3579-84. PubMed ID: 7438044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative and qualitative aspects of the binding of N-hydroxy-2-acetylaminofluorene to hepatic chromatin fractions.
    Schwartz EL; Goodman JI
    Chem Biol Interact; 1979 Aug; 26(3):287-303. PubMed ID: 509692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aryl sulfotransferase IV deficiency in rat liver carcinogenesis initiated with diethylnitrosamine and promoted with N-2-fluorenylacetamide or its C-9-oxidized metabolites.
    Malejka-Giganti D; Ringer DP; Vijayaraghavan P; Kiehlbauch CC; Kong J
    Exp Mol Pathol; 1997 Apr; 64(2):63-77. PubMed ID: 9316585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late target protein of the carcinogen N-2-fluorenylacetamide in rat liver.
    Munir KM; Blackburn GR; Sorof S
    Cancer Res; 1988 Dec; 48(23):6745-52. PubMed ID: 3180085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-2-fluorenylacetamide-induced conformational and functional damage to DNA.
    Grunberger D
    Natl Cancer Inst Monogr; 1981 Dec; (58):193-9. PubMed ID: 7341976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and quantitation of acetylated and deacetylated N-2-fluorenylacetamide-DNA adducts by radioimmunoassay.
    Poirier MC; Yuspa SH
    Natl Cancer Inst Monogr; 1981 Dec; (58):211-6. PubMed ID: 7341978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo binding of N-2-acetylaminofluorene and its N-hydroxy derivative to the DNA of fractionated rat liver chromatin.
    Walker MS; Becker FF; Rodriguez LV
    Chem Biol Interact; 1979 Oct; 27(2-3):177-90. PubMed ID: 498353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxidative metabolism of a carcinogen, N-hydroxy-N-2-fluorenylacetamide, by rat uterus and mammary gland in vitro.
    Malejka-Giganti D; Ritter CL; Decker RW; Suilman JM
    Cancer Res; 1986 Dec; 46(12 Pt 1):6200-6. PubMed ID: 3779640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of the inhibitory action of p-hydroxyacetanilide on carcinogenesis by N-2-fluorenylacetamide or N-hydroxy-N-2-fluorenylacetamide.
    Mohan LC; Grantham PH; Weisburger EK; Weisburger JH; Idoine JB
    J Natl Cancer Inst; 1976 Apr; 56(4):763-8. PubMed ID: 815562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of N-2-fluorenylacetamide-induced mammary tumorigenesis in rats by dietary polybrominated biphenyls.
    Schwartz EL; Kluwe WM; Sleight SD; Hook JB; Goodman JI
    J Natl Cancer Inst; 1980 Jan; 64(1):63-7. PubMed ID: 6243377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolite profile in milk of lactating rats after treatment with a carcinogen, N-2-fluorenylacetamide.
    Malejka-Giganti D; Magat WJ; Adelmann AM; Decker RW
    Drug Metab Dispos; 1987; 15(6):760-6. PubMed ID: 2893699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute or chronic treatment of rats with N-2-fluorenylacetamide on its N-hydroxylation and on hemoproteins of hepatic microsomes.
    Malejka-Giganti D; Ritter CL
    Res Commun Chem Pathol Pharmacol; 1980 Apr; 28(1):53-64. PubMed ID: 7394317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro binding of N-acetoxy-N-2-acetylaminofluorene to DNA in chromatin.
    Metzger G; Daune MP
    Cancer Res; 1975 Oct; 35(10):2738-42. PubMed ID: 1157048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P-450- and flavin-containing monooxygenase-catalyzed formation of the carcinogen N-hydroxy-2-aminofluorene and its covalent binding to nuclear DNA.
    Frederick CB; Mays JB; Ziegler DM; Guengerich FP; Kadlubar FF
    Cancer Res; 1982 Jul; 42(7):2671-7. PubMed ID: 7083159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonrandom nature of in vivo methylation of dimethylnitrosamine and the subsequent removal of methylated products from rat liver chromatin DNA.
    Ramanathan R; Rajalakshmi S; Sarma DS; Farber E
    Cancer Res; 1976 Jun; 36(6):2073-9. PubMed ID: 1268860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of N-2-acetylaminofluorene modification on the structure and template activity of DNA and reconstituted chromatin.
    Yamasaki H; Leffler S; Weinstein IB
    Cancer Res; 1977 Mar; 37(3):684-91. PubMed ID: 837369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammary carcinogenesis in the rat by topical application of fluorenylhydroxamic acids and their acetates.
    Malejka-Giganti D; Rydell RE; Gutmann HR
    Cancer Res; 1977 Jan; 37(1):111-7. PubMed ID: 830400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-random interaction of N-2-acetylaminofluorene and its N-hydroxy metabolite with DNA of rat hepatic parenchymal and non-parenchymal cell nuclei following in vivo administration of carcinogen.
    Baranyi-Furlong BL; Goodman JI
    Chem Biol Interact; 1984 Jan; 48(1):15-28. PubMed ID: 6692493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutagenic activation of N-2-fluorenylacetamide and N-hydroxy-N-2-fluorenylacetamide in subcellular fractions from X/Gf mice.
    Reddy TV; Weisburger EK; Thorgeirsson SS
    J Natl Cancer Inst; 1980 Jun; 64(6):1563-9. PubMed ID: 6929392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.